Targeting bladder cancer using CRISPR technology
Precision targeting of bladder cancer using CRISPR
This study is exploring a new way to treat bladder cancer using a special technology called CRISPR that targets the specific genetic changes causing the cancer, aiming to make the treatment more effective and with fewer side effects, and it will first be tested in mice before moving to humans.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11031959 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat bladder cancer by using CRISPR technology to specifically target and disrupt genetic alterations that drive tumor growth. The method, known as KLIPP, utilizes a split enzyme system to create targeted DNA breaks in cancer cells while sparing normal cells. By focusing on structural variant junctions unique to bladder cancer, this approach aims to improve treatment efficacy and reduce side effects. The research will involve pre-clinical testing in mouse models to evaluate the effectiveness of this targeted therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with locally invasive bladder cancer who have limited treatment options.
Not a fit: Patients with non-invasive bladder cancer or those who do not have structural variants in their tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with bladder cancer.
How similar studies have performed: Other research has shown promising results using CRISPR technology for cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Ljungman, Mats — University of Michigan at Ann Arbor
- Study coordinator: Ljungman, Mats
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.